Healthcare Industry News:  orally disintegrating tablet 

Biopharmaceuticals Litigation

 News Release - August 4, 2006

Eisai Commences U.S. Legal Action Over Aricept ODT(R) ANDA Filing

TOKYO and TEANECK, N.J., Aug. 4 (HSMN NewsFeed) -- Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) today announce that they have filed a lawsuit against Mutual Pharmaceutical Co., Ltd. and United Research Laboratories, Inc. regarding its submission of an abbreviated new drug application (ANDA) to the FDA for Aricept ODT® orally disintegrating tablets (Active Ingredient Name: donepezil hydrochloride). Eisai's action was filed in the U.S. District Court for the District of New Jersey in Newark on August 3, 2006.

Eisai believes that its donepezil composition patent is valid until its expiration date of November 25, 2010. Eisai intends to vigorously enforce and defend that patent.

Aricept® is an acetylcholinesterase inhibitor and is believed to work by inhibiting the breakdown of acetylcholine, thereby increasing available levels of this chemical in the brain.

Eisai's corporate human health care (hhc) mission is to give first thought to patients and their families, and to increase the benefits that health care provides. The company believes that increasing patient satisfaction through the development of innovative new medicines exemplifies its important mission.


Source: Eisai

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.